Re-evaluating the role of BCR/ABL in chronic myelogenous leukemia
TS Ross, VE Mgbemena - Molecular & cellular oncology, 2014 - Taylor & Francis
Chronic myelogenous leukemia (CML) requires the BCR/ABL tyrosine kinase for disease
onset and maintenance. As a result, CML can be successfully treated with tyrosine kinase …
onset and maintenance. As a result, CML can be successfully treated with tyrosine kinase …
Chronic myeloid leukemia in the era of tyrosine kinase inhibitors: an evolving paradigm of molecularly targeted therapy
MAM Ali - Molecular diagnosis & therapy, 2016 - Springer
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm, characterized by the
unrestrained expansion of pluripotent hematopoietic stem cells. CML was the first …
unrestrained expansion of pluripotent hematopoietic stem cells. CML was the first …
Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions
AEG Osman, MW Deininger - Blood reviews, 2021 - Elsevier
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by a reciprocal
translocation [t (9; 22)(q34; q11. 2)] that leads to the fusion of ABL1 gene sequences (9q34) …
translocation [t (9; 22)(q34; q11. 2)] that leads to the fusion of ABL1 gene sequences (9q34) …
Development of an effective therapy for chronic myelogenous leukemia
DW Woessner, CS Lim, MW Deininger - The Cancer Journal, 2011 - journals.lww.com
Targeted small-molecule drugs have revolutionized treatment of chronic myeloid leukemia
(CML) during the last decade. These agents interrupt a constitutively active BCR-ABL, the …
(CML) during the last decade. These agents interrupt a constitutively active BCR-ABL, the …
Therapy of chronic myeloid leukemia: twilight of the imatinib era?
E Trela, S Glowacki, J Błasiak - … Scholarly Research Notices, 2014 - Wiley Online Library
Chronic myeloid leukemia (CML) results from the clonal expansion of pluripotent
hematopoietic stem cells containing the active BCR/ABL fusion gene produced by a …
hematopoietic stem cells containing the active BCR/ABL fusion gene produced by a …
The CML stem cell: evolution of the progenitor
SA Stuart, Y Minami, JYJ Wang - Cell cycle, 2009 - Taylor & Francis
The success of Imatinib mesylate (STI571, Gleevec) in treating chronic myeloid leukemia
(CML) is, to date, the crowning achievement of targeted molecular therapy in cancer. Nearly …
(CML) is, to date, the crowning achievement of targeted molecular therapy in cancer. Nearly …
Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring
E Jabbour, H Kantarjian - American journal of hematology, 2022 - Wiley Online Library
Abstract Disease Overview Chronic Myeloid Leukemia (CML) is a myeloproliferative
neoplasm with an incidence of 1–2 cases per 100 000 adults. It accounts for approximately …
neoplasm with an incidence of 1–2 cases per 100 000 adults. It accounts for approximately …
Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring
E Jabbour, H Kantarjian - American journal of hematology, 2020 - Wiley Online Library
Disease overview Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with an
incidence of 1‐2 cases per 100 000 adults. It accounts for approximately 15% of newly …
incidence of 1‐2 cases per 100 000 adults. It accounts for approximately 15% of newly …
Chronic myeloid leukemia, from pathophysiology to treatment-free remission: a narrative literature review
I Rinaldi, K Winston - Journal of Blood Medicine, 2023 - Taylor & Francis
Chronic myeloid leukemia (CML) is one of the most common leukemias occurring in the
adult population. The course of CML is divided into three phases: the chronic phase, the …
adult population. The course of CML is divided into three phases: the chronic phase, the …
Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring
E Jabbour, H Kantarjian - American journal of hematology, 2018 - Wiley Online Library
Disease overview Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with an
incidence of 1‐2 cases per 100 000 adults. It accounts for approximately 15% of newly …
incidence of 1‐2 cases per 100 000 adults. It accounts for approximately 15% of newly …